Patricia Van Arnum

Editorial Director, DCAT

[email protected]
Patricia Van Arnum is Editorial Director at the Drug, Chemical & Associated Technologies Association (DCAT), where she is responsible for delivering informational services for DCAT members. She is editor of DCAT Value Chain Insights, DCAT’s editorial newsletter providing news and analysis of the business of bio/pharmaceutical development and manufacturing covering the full spectrum of the bio/pharmaceutical manufacturing value chain. She also provides content advisement and support for DCAT’s volunteer committees. Overall, she has 30 years of experience covering the Bio/Pharmaceutical, Fine-Chemical and Chemical industries as a business and science editor. She is a member of the American Chemical Society, the American Association of Pharmaceutical Scientists, and the American Association for the Advancement of Science and holds undergraduate degrees in chemistry, economics, and political science.

LATEST

Oral Obesity Drug Battle Is On with FDA OK for Lilly’s Orforglipron
By

By
Lilly is entering the oral obesity drug market by gaining FDA approval for Foundayo (orforglipron), a small-molecule (non-peptide) oral GLP-1 receptor agonist, setting up head-on competition with an oral version of Novo Nordisk’s obesity drug, Wegovy (semaglutide).

What is Top of the Industry’s Sustainability Agenda in 2026?
By

By
Decarbonizing, standardized reporting of value-chain emissions, and coalescing talent and technology are high on the industry’s sustainability agenda in 2026.

Change, Change, & Change: The Pharma Industry’s Outlook & Response
By

By
The bio/pharma industry faces geopolitical uncertainties, fluid trade conditions, and greater product and supply-chain complexity. What lies ahead for bio/pharma companies and suppliers? An outlook for the industry. 

Future-Proofing the Pharma Customer & Supplier Relationship
By

By
The US Supreme Court ruling on reciprocal tariffs is the latest turn in a fluid global trade situation. How can pharma companies and their suppliers adapt? An executive panel at DCAT Week will share ways on how they are collaborating.

AI: The State of the State in Supply Management 
By

By
AI and digitalization hold great potential in transforming business functions, but where do they really stand in supply management? An executive panel at DCAT Week will share their perspectives on how AI may transform how pharma companies and their suppliers do business.

What’s in Store for Pharma in 2026 & Beyond?
By

By
Evolving tariff/trade policy, US drug pricing reforms, and a changing global landscape are contributing to an uncertain environment. A DCAT Week education program, featuring experts from IQVIA, will provide in-depth insights on pharma industry performance. 

Manufacturing Outlook: A Pharma & CDMO View
By

By
The wave of US pharmaceutical manufacturing investments has garnered the headlines, but are geographic capacity shifts really in the making? A DCAT Week education program will provide expert analysis, including on the all-important, “make-versus-buy” decision.

Blockbuster Contenders: The Class of 2026
By

By
What new products, recently or expected to launch in 2026, show blockbuster potential or will be transformative in key therapeutic areas? A look at the companies and products rising to the top of the class. 

CDMOs Roll Out Expansions for Parenteral Drugs
By

By
The global injectables drugs market is projected for strong growth, driven by demand in biologics and specialty therapeutics. In response, CDMOs/CMOS are expanding production capacity. What are the latest expansions?

Big Pharma Outlook: CEOs Making the Moves
By

By
As the industry moves further into 2026, what are larger issues impacting industry and company performance? .A view from the C-suite.